Kidney Week

Abstract: SA-PO1083

Glomerular Staining and Serum Antibodies of THSD7A in Malignancy-Associated Membranous Nephropathy

Session Information

• Pathology and Lab Medicine: Clinical
  October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Pathology and Lab Medicine

• 1502 Pathology and Lab Medicine: Clinical

Authors

• Zhang, Changming, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

Changming Zhang,

• Zhang, Ming-chao, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

Ming-chao Zhang,

• Chen, Da cheng, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China, Nanjing, China

Da cheng Chen,

• Ren, Qiang, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

Qiang Ren,

• Xu, Weiwei, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

Weiwei Xu,

• Qin, Wei-song, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

Wei-song Qin,

• Liu, Zhihong, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

Zhihong Liu,

Background

Thrombospondin type 1 domain-containing 7A (THSD7A) is recently identified as the target antigen in patients with membranous nephropathy (MN). A notable phenomenon is the high rate of cancer (reported to be as high as 20%) in patients with THSD7A-associated MN. The prevalence of THSD7A in patients with malignancy-associated MN deserves further clarification.

Methods

Glomerular expression of THSD7A was examined by immunohistochemistry in 36 patients with malignancy-associated MN. Immunofluorescence assay was performed to investigate anti-THSD7A antibodies. Anti-PLA2R antibodies and glomerular PLA2R expression was also screened. THSD7A expression of cancer tissues was tested in 9 among the 36 patients.

Results

Among the 36 patients with malignancy-associated MN, 3 (8.3%) patients were identified as glomerular THSD7A staining positive: one patient was THSD7A positive alone, which accounted for 6.3% (one of 16) of PLA2R negative patients; two patients were dual-positive for both THSD7A and PLA2R staining. No anti-THSD7A antibody was detected among the 36 patients, whereas 18 of 36 (50%) had anti-PLA2R antibodies. Among the 9 patients who were available for cancer THSD7A staining, five (56%) patients showed enhanced expression of THSD7A localized in cancer tissue: one patient also had enhanced expression of THSD7A in glomeruli.

Conclusion

We found that positive glomerular THSD7A staining was uncommon in patiens with malignancy-associated MN.